Literature DB >> 1919892

Treatment of chronic cryptosporidial infection with orally administered human serum immune globulin.

S M Borowitz1, F T Saulsbury.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1919892     DOI: 10.1016/s0022-3476(05)82412-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  7 in total

1.  Enteral human serum immunoglobulin treatment of cryptosporidiosis in mice with severe combined immunodeficiency.

Authors:  T L Kuhls; S L Orlicek; D A Mosier; D L Crawford; V L Abrams; R A Greenfield
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

Review 2.  The immunology of parasite infections in immunocompromised hosts.

Authors:  T Evering; L M Weiss
Journal:  Parasite Immunol       Date:  2006-11       Impact factor: 2.280

3.  Lack of effect of orally administered human serum immunoglobulin on the normal human oral and intestinal microflora.

Authors:  A K Bogstedt; C E Nord; L Hammarström
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-01       Impact factor: 3.267

4.  Bovine colostrum immunoglobulin concentrate for cryptosporidiosis in AIDS.

Authors:  P Heaton
Journal:  Arch Dis Child       Date:  1994-04       Impact factor: 3.791

5.  A double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder.

Authors:  Benjamin L Handen; Raun D Melmed; Robin L Hansen; Michael G Aman; David L Burnham; Jon B Bruss; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2009-01-16

Review 6.  Clinical significance of enteric protozoa in the immunosuppressed human population.

Authors:  D Stark; J L N Barratt; S van Hal; D Marriott; J Harkness; J T Ellis
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

Review 7.  Antibody-based therapies for emerging infectious diseases.

Authors:  A Casadevall
Journal:  Emerg Infect Dis       Date:  1996 Jul-Sep       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.